FealtySign in
Promise-keeping streak4 kept in a rowguidance & buyback

CLOROX CO /DE/

(CLX)

CIK 21076 · SEC filings only

Not gradedDividend record
shown as history
company entity
65 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

65 declarations · 13 raised · 43 held · 0 cut · held 56 quarters

  1. HELD$1.2400/shperiod ended 2026-03-31Filing ↗
  2. NOTED$1.2400/shperiod ended 2025-12-31Filing ↗
  3. NOTED$2.4800/shperiod ended 2025-09-30Filing ↗
  4. HELD$1.2200/shperiod ended 2025-03-31Filing ↗
  5. NOTED$1.2200/shperiod ended 2024-12-31Filing ↗
  6. NOTED$2.4400/shperiod ended 2024-09-30Filing ↗
  7. HELD$1.2000/shperiod ended 2024-03-31Filing ↗
  8. NOTED$1.2000/shperiod ended 2023-12-31Filing ↗
  9. NOTED$2.4000/shperiod ended 2023-09-30Filing ↗
  10. HELD$1.1800/shperiod ended 2023-03-31Filing ↗
  11. NOTED$1.1800/shperiod ended 2022-12-31Filing ↗
  12. NOTED$2.3600/shperiod ended 2022-09-30Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
1 resolved promise

Not enough resolved promises to grade

1 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Credibility timeline

KEPT · Nov 2, 2020
20202020
Timeline as a list
  • Nov 2, 2020KEPTthe company currently plans to repurchase about half the full amount in fiscal year 2019
1 resolved buyback promise · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
B−Guidance record
grade
company entity
12 resolved promises

Sector median (Industrial Applications and Services): B+ across 28 graded companies

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance by basis

16 of 28 guidance figures that were graded or dropped for basis could not be graded on the same basis (57%). Guidance marked “not judged” is in neither number.

Guidance typeSaidGradedDroppedOther
Revenue · non-GAAPcannot be graded1010
Revenue · basis not stated367029
EPS · GAAP175012
EPS · non-GAAPcannot be graded240717
EPS · basis not statedcannot be graded190811

Said counts every revenue and EPS guidance figure on record. Dropped counts figures whose period was reported but which have no comparable GAAP actual in SEC XBRL. Other covers open, superseded, withdrawn and otherwise unresolved figures. The coverage note below counts every figure shown but not graded, including figures whose period has not been reported, so it can be larger.

How the site-wide rate is measured

Compare across companies

Guidance shown, not graded (46)

We show what was said — with its source filing — but never score it. The line under each statement says why.

  1. eps guidance fy · Aug 3, 2026
    Adjusted EPS is expected to be between $5.70 and $6.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. eps guidance fy · Apr 30, 2026
    Adjusted EPS is now expected to be between $5.45 and $5.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Feb 3, 2026
    Adjusted EPS is still expected to be between $5.95 and $6.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Feb 3, 2026
    Fiscal year diluted EPS is still expected to be between $5.60 and $5.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance fy · Nov 3, 2025
    Fiscal year diluted EPS is still expected to be between $5.60 and $5.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Nov 3, 2025
    Adjusted EPS is still expected to be between $5.95 and $6.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance fy · Jul 31, 2025
    Adjusted EPS is expected to be between $5.95 and $6.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · May 5, 2025
    Adjusted EPS is expected to be between $6.95 and $7.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. revenue guidance fy · May 5, 2025
    Organic sales are now expected to grow 4% to 5%
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · Feb 3, 2025
    Adjusted EPS is now expected to be between $6.95 and $7.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance fy · Oct 30, 2024
    Adjusted EPS is now expected to be between $6.65 and $6.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. eps guidance fy · Aug 1, 2024
    Adjusted EPS is expected to be between $6.55 and $6.80
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance fy · Apr 30, 2024
    Adjusted EPS is now expected to be between $5.80 and $5.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Feb 1, 2024
    Adjusted EPS is now expected to be between $5.30 and $5.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. eps guidance fy · Feb 1, 2024
    fiscal year diluted EPS is now expected to be between $3.06 and $3.26
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance fy · Nov 1, 2023
    fiscal year diluted EPS is now expected to be between $2.10 and $2.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Nov 1, 2023
    Adjusted EPS is now expected to be between $4.30 and $4.80
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. revenue guidance q · Oct 4, 2023
    Net sales are expected to decrease by 28% to 23% from the year-ago quarter.
    Not judged — this statement was filed after the period it is stored under had ended, so it is not guidance for that period.Filing ↗
  19. eps guidance q · Oct 4, 2023
    Diluted net earnings per share (diluted EPS) is expected to be between a loss of $0.75 to a loss of $0.35.
    Not judged — this statement was filed after the period it is stored under had ended, so it is not guidance for that period.Filing ↗
  20. eps guidance q · Oct 4, 2023
    Adjusted EPS is expected to be a loss of $0.40 to $0.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. eps guidance fy · Aug 2, 2023
    Adjusted EPS is expected to be between $5.60 and $5.90
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance fy · May 2, 2023
    Adjusted EPS is now expected to be between $4.35 and $4.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. eps guidance fy · May 2, 2023
    Diluted EPS is now expected to be between $0.45 and $0.60
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. eps guidance fy · Feb 2, 2023
    Adjusted EPS is now expected to be between $4.05 and $4.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · Nov 1, 2022
    Adjusted EPS between $3.85 and $4.22
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance fy · Aug 3, 2022
    Adjusted EPS is expected to be between $3.85 and $4.22
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. eps guidance fy · May 2, 2022
    Adjusted EPS is now expected to be between $4.05 and $4.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  28. eps guidance fy · Feb 3, 2022
    Adjusted EPS between $4.25 and $4.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. eps guidance fy · Nov 1, 2021
    Adjusted EPS between $5.40 and $5.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. eps guidance fy · Nov 1, 2021
    Diluted EPS between $5.05 and $5.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. eps guidance fy · Aug 3, 2021
    Adjusted EPS is projected to be between $5.40 and $5.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  32. eps guidance fy · Apr 30, 2021
    and adjusted EPS to increase between 1% and 4%, or $7.45 to $7.65
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  33. eps guidance fy · Feb 4, 2021
    Clorox now anticipates fiscal year 2021 diluted EPS to increase between 9% and 12%, or $8.05 to $8.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  34. eps guidance fy · Nov 2, 2020
    Clorox now anticipates fiscal year 2021 diluted EPS to increase between 5% and 8%, or $7.70 to $7.95
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  35. eps guidance fy · Aug 3, 2020
    Net of all these factors, Clorox anticipates fiscal year 2021 diluted EPS range is expected to be from a mid-single-digit decrease to a mid-single-digit increase
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  36. eps guidance fy · Feb 4, 2020
    $6.10-$6.25 diluted EPS range
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  37. eps guidance fy · Aug 1, 2019
    Clorox anticipates fiscal year 2020 diluted EPS from continuing operations to be in the range of $6.30 to $6.50
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  38. eps guidance fy · May 1, 2019
    Clorox now expects fiscal year 2019 diluted EPS from continuing operations to be in the range of $6.25 to $6.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  39. eps guidance fy · Feb 4, 2019
    Net of all these factors, Clorox expects fiscal year 2019 diluted EPS from continuing operations to remain in the range of $6.20 to $6.40
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  40. eps guidance fy · Aug 2, 2018
    Clorox anticipates fiscal year 2019 diluted EPS from continuing operations to be in the range of $6.32 to $6.52
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  41. eps guidance fy · May 2, 2018
    Clorox now anticipates fiscal year 2018 diluted EPS from continuing operations to be in the range of $6.15 to $6.30
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  42. eps guidance fy · Nov 1, 2017
    Clorox now anticipates fiscal year 2018 diluted EPS from continuing operations to be in the range of $5.47 to $5.67
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  43. eps guidance fy · Nov 2, 2016
    Clorox now anticipates fiscal year 2017 diluted EPS from continuing operations to be in the range of $5.23 to $5.43
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  44. eps guidance fy · Nov 2, 2016
    Excluding the benefit of adopting the accounting standards update, Clorox continues to anticipate fiscal year 2017 diluted EPS from continuing operations to be in the range of $5.13 to $5.28
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  45. eps guidance fy · Jul 15, 2008
    The company now anticipates fiscal 2008 diluted EPS in the range of $3.22-$3.25
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  46. eps guidance fy · Feb 4, 2008
    the company’s outlook for diluted EPS is now in the range of $3.20 to $3.35
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (7) · 31 superseded

Open · revenue guidance fy

For fiscal year 2008, Clorox now anticipates sales growth in the range of 6-7 percent

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance q

Fourth-quarter sales are expected to be in the range of 10-11 percent

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

The company continues to expect net sales to be down low single digits.

unresolved — no outcome on filereceipt (opens in a new tab)
Open · revenue guidance fy

The company now expects net sales to be down about 6%

resolves in ~153 daysreceipt (opens in a new tab)
Open · eps guidance fy

Fiscal year diluted EPS is now expected to be between $4.78 and $4.98

resolves in ~153 daysreceipt (opens in a new tab)
Open · eps guidance fy

Diluted EPS is expected to be between $5.41 and $5.71

resolves in ~519 daysreceipt (opens in a new tab)
Open · revenue guidance fy

Net sales are expected to be up 13% to 14% compared to the prior year

resolves in ~519 daysreceipt (opens in a new tab)
Superseded · eps guidance fy

Diluted EPS is expected to be between $4.65 and $4.95

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Clorox anticipates fiscal year 2022 diluted EPS to be between $5.05 and $5.35

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales are expected to be flat to up 2% compared to the prior year.

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales are now expected to be down low single digits

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Clorox’s fiscal year sales are now expected to grow between 10% and 13%

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

The company still expects net sales to be down 6% to 10%

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Diluted EPS is expected to be between $4.95 and $5.20

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Clorox anticipates sales growth ranging from flat to 2%

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales are expected to be down 6% to 10% compared to the prior year.

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales are now expected to be between a 2% decrease to a 1% increase

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Clorox’s fiscal year sales are now expected to grow between 5% and 9%

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Diluted EPS is expected to be between $3.10 and $3.47

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales are expected to be flat to down 2% compared to the prior year.

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Clorox anticipates sales growth ranging from flat to low single digits

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Fiscal year diluted EPS is now expected to be between $5.52 and $5.92

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

The company continues to expect net sales to be flat to down 2%

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Diluted EPS between $3.80 and $4.05

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Fiscal year diluted EPS is now expected to be between $5.17 and $5.42

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales decline of 1% to 4%

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Diluted EPS between $3.10 and $3.47

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Clorox now anticipates sales growth in the range of 1 percent to 3 percent

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Clorox’s 2022 fiscal year sales are projected to be down 2% to 6%

revised by a later guidancereceipt (opens in a new tab)
Superseded · eps guidance fy

Diluted EPS is expected to be between $5.60 and $5.95

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales decline of 2% to 6%

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales from a 4% decrease to a 2% increase compared to the prior year

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales are now expected to be down mid- to high single digits

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

The company now expects net sales to be down 1% to up 2%

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Clorox continues to anticipate sales growth in the range of 2 to 4 percent

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

The company still expects net sales to be down 6% to 10%

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Net sales are expected to be down 4% to up 2% compared to the prior year.

revised by a later guidancereceipt (opens in a new tab)
Superseded · revenue guidance fy

Clorox anticipates sales growth in the range of 2 percent to 4 percent

revised by a later guidancereceipt (opens in a new tab)

Credibility timeline

IN LINE · Aug 15, 2017IN LINE · Aug 14, 2018UNRESOLVABLE · May 1, 2019ABOVE · Aug 13, 2020BELOW · Aug 10, 2021BELOW · Aug 10, 2021IN LINE · Aug 10, 2022IN LINE · Aug 10, 2022ABOVE · Aug 10, 2023BELOW · Aug 10, 2023ABOVE · Aug 8, 2024ABOVE · Aug 8, 2025ABOVE · Aug 8, 2025
20172025
Timeline as a list
  • Aug 15, 2017IN LINEClorox continues to anticipate delivering 2 percent to 4 percent sales growth in fiscal year 2017
  • Aug 14, 2018IN LINEClorox now anticipates fiscal year 2018 sales growth at about 3 percent
  • May 1, 2019UNRESOLVABLEClorox now anticipates sales growth in the range of 2% to 3%
  • Aug 13, 2020ABOVELow single-digit decrease to 1% increase in sales
  • Aug 10, 2021BELOWClorox’s fiscal year sales are still expected to grow between 10% and 13%
  • Aug 10, 2021BELOWNet of all these factors, Clorox now anticipates fiscal year 2021 diluted EPS to decrease between 19% and 16%, or $5.94 to $6.14
  • Aug 10, 2022IN LINENet sales are still expected to decrease 1% to 4%
  • Aug 10, 2022IN LINEDiluted EPS is now expected to be between $3.60 and $3.85
  • Aug 10, 2023ABOVENet sales are now expected to be between a 1% and 2% increase
  • Aug 10, 2023BELOWDiluted EPS is now expected to be between $3.20 and $3.45
  • Aug 8, 2024ABOVEfiscal year diluted EPS is now expected to be between $1.66 and $1.81
  • Aug 8, 2025ABOVEThe company now expects net sales to be down 1% to flat
  • Aug 8, 2025ABOVEFiscal year diluted EPS is now expected to be between $5.73 and $6.13
12 resolved guidance promises · 47 not graded (no comparable reported figure) · resolver resolver-v5 · score score-v1. Every verdict links to its source filing. Full methodology →